TAVR for Aortic Valve Disease

Recruiting now

Conditions studied: Aortic Valve Disease

In brief

Transcatheter aortic valve replacement (TAVR) has became an important treatment of severe aortic stenosis (AS). Several randomized clinical trials showed that TAVR was non-inferior or superior to surgical aortic valve replacement (SAVR). However, many different issues have emerged: TAVR in younger patients? valve leaflet thrombosis? transcatheter valve durability? coronary reaccess after TAVR? TAVR in bicuspid aortic valve? TAVR in aortic regurgitation? etc. Hence, a prospective, multicenter database is created to provide the real-word data for these questions.

Key facts

Study ID

NCT05439863

Run by

Nanjing First Hospital, Nanjing Medical University

People needed

5000

Starts

2022-07-01

Expected to finish

2037-12-30

Last updated by the study team

2024-11-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Clinical diagnosis of severe aortic stenosis or aortic regurgitation
• Patients undergo transcatheter aortic valve replacement

You may not qualify if…

• patients refuse the clinical follow-up

Where it is running

• Nanjing First Hospital — Nanjing, Jiangsu, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.